Blood marker may reveal who benefits from ED drug

NCT ID NCT07479901

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test measuring the 'atherogenic index' can predict how well the drug tadalafil works for men with erectile dysfunction caused by blood vessel problems. Researchers will give 132 men tadalafil daily for one month and compare their symptom scores before and after treatment. The goal is to see if this simple blood marker can help personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tadalafil
What this could lead to
If successful, this could help doctors predict which men with erectile dysfunction will respond best to tadalafil based on a simple blood test.
What could go wrong
This is a small, observational study, not a large trial. The link between the blood marker and treatment response may not be strong enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERECTILE DYSFUNCTION VASCULAR ERECTILE DYSFUNCTION ATHEROGENIC DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taksim Training and Research Hospital, Istanbul

    Istanbul, Beyoğlu, 34433, Turkey (Türkiye)